Abstract
Prostate cancer is a common malignant tumor and the second leading cause of cancer-related death in men. Radiation therapy is a curative treatment for localized prostate cancer and has a limited effect for castration-resistant prostate cancer (CRPC). Interleukin 24 (IL-24) has a radiosensitizing effect in cancer cells. Our previous studies showed that ZD55-IL-24, an oncolytic adenovirus harboring IL-24, had better anti-tumor effect with no toxicity to normal cells. In this study, we evaluated the synergistic anti-tumor effect of oncolytic adenovirus ZD55-IL-24 combined with radiotherapy in prostate cancer. In Vitro and In Vivo experiments showed that the combined therapy significantly inhibited the growth of prostate cancer and provoked apoptosis of prostate cancer cells. In conclusion, the combination of ionizing radiation and oncolytic adenovirus expressing IL24 could achieve synergistic anti-tumor effect on prostate cancer, and is a promising strategy for prostate cancer therapy.
Highlights
Prostate cancer is a common cancer in the male [1]
ZD55-Interleukin 24 (IL-24) inhibited the proliferation of PC-3 and DU-145 cells in a time and dose dependent manner (Figures 1A,B, P < 0.01)
The protein levels of Caspase-3 and Caspase-8 in combination group were significantly higher than in monotherapy group (Figure 3B, P < 0.05), while B-cell lymphoma-2 (Bcl-2) protein levels in combination group were significantly lower than in monotherapy group (Figure 3B, P < 0.01). These results indicated that ZD55IL-24 and radiation modulated the expression of apoptosis related proteins
Summary
Prostate cancer is a common cancer in the male [1]. Prostatectomy, radiation therapy, chemotherapy, and androgen deprivation therapy are main methods for the treatment of prostate cancer [2].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
